BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29692895)

  • 1. Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities.
    Garrett M; Sperry J; Braas D; Yan W; Le TM; Mottahedeh J; Ludwig K; Eskin A; Qin Y; Levy R; Breunig JJ; Pajonk F; Graeber TG; Radu CG; Christofk H; Prins RM; Lai A; Liau LM; Coppola G; Kornblum HI
    Cancer Metab; 2018; 6():4. PubMed ID: 29692895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas.
    Fujita Y; Nunez-Rubiano L; Dono A; Bellman A; Shah M; Rodriguez JC; Putluri V; Kamal AHM; Putluri N; Riascos RF; Zhu JJ; Esquenazi Y; Ballester LY
    J Neurooncol; 2022 Sep; 159(2):261-270. PubMed ID: 35816267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered metabolic landscape in IDH-mutant gliomas affects phospholipid, energy, and oxidative stress pathways.
    Fack F; Tardito S; Hochart G; Oudin A; Zheng L; Fritah S; Golebiewska A; Nazarov PV; Bernard A; Hau AC; Keunen O; Leenders W; Lund-Johansen M; Stauber J; Gottlieb E; Bjerkvig R; Niclou SP
    EMBO Mol Med; 2017 Dec; 9(12):1681-1695. PubMed ID: 29054837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R132H IDH1 sensitizes glioma to the antiproliferative and cytotoxic effects of BET inhibition.
    Sears TK; Woolard KD
    J Cancer Res Clin Oncol; 2022 Sep; 148(9):2275-2285. PubMed ID: 35467128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Metabolomic Analysis of IDH1
    Miyata S; Tominaga K; Sakashita E; Urabe M; Onuki Y; Gomi A; Yamaguchi T; Mieno M; Mizukami H; Kume A; Ozawa K; Watanabe E; Kawai K; Endo H
    Sci Rep; 2019 Jul; 9(1):9787. PubMed ID: 31278288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The neural stem-cell marker CD24 is specifically upregulated in IDH-mutant glioma.
    Tiburcio PDB; Locke MC; Bhaskara S; Chandrasekharan MB; Huang LE
    Transl Oncol; 2020 Oct; 13(10):100819. PubMed ID: 32622311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase.
    Izquierdo-Garcia JL; Cai LM; Chaumeil MM; Eriksson P; Robinson AE; Pieper RO; Phillips JJ; Ronen SM
    PLoS One; 2014; 9(9):e108289. PubMed ID: 25243911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin.
    Biedermann J; Preussler M; Conde M; Peitzsch M; Richter S; Wiedemuth R; Abou-El-Ardat K; Krüger A; Meinhardt M; Schackert G; Leenders WP; Herold-Mende C; Niclou SP; Bjerkvig R; Eisenhofer G; Temme A; Seifert M; Kunz-Schughart LA; Schröck E; Klink B
    Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31888244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
    Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
    J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
    Chitneni SK; Reitman ZJ; Gooden DM; Yan H; Zalutsky MR
    Eur J Med Chem; 2016 Aug; 119():218-30. PubMed ID: 27163884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.
    Chen YY; Ho HL; Lin SC; Hsu CY; Ho DM
    Neurosurgery; 2019 Sep; 85(3):335-342. PubMed ID: 30113684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isocitrate dehydrogenase1 mutation reduces the pericyte coverage of microvessels in astrocytic tumours.
    Sun C; Zhao Y; Shi J; Zhang J; Yuan Y; Gu Y; Zhang F; Gao X; Wang C; Wang Y; Wang Z; Hu P; Qin J; Xiao L; Chang T; Wang L; Xi Y; Yin H; Chen H; Zhang L; Cheng G; Lin J; Zhang M; Li Z; Ye J
    J Neurooncol; 2019 Jun; 143(2):187-196. PubMed ID: 31004262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GABA, glutamine, glutamate oxidation and succinic semialdehyde dehydrogenase expression in human gliomas.
    Hujber Z; Horváth G; Petővári G; Krencz I; Dankó T; Mészáros K; Rajnai H; Szoboszlai N; Leenders WPJ; Jeney A; Tretter L; Sebestyén A
    J Exp Clin Cancer Res; 2018 Nov; 37(1):271. PubMed ID: 30404651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
    Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
    FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
    Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
    Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas.
    Suzuki K; Kawai N; Ogawa T; Miyake K; Shinomiya A; Yamamoto Y; Nishiyama Y; Tamiya T
    EJNMMI Res; 2021 Jul; 11(1):67. PubMed ID: 34291337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant IDH and non-mutant chondrosarcomas display distinct cellular metabolomes.
    Pathmanapan S; Ilkayeva O; Martin JT; Loe AKH; Zhang H; Zhang GF; Newgard CB; Wunder JS; Alman BA
    Cancer Metab; 2021 Mar; 9(1):13. PubMed ID: 33762012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
    Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
    PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative Determination of Isocitrate Dehydrogenase Mutation in Gliomas Using Spectral Editing MRS: A Prospective Study.
    Nguyen TB; Melkus G; Taccone M; Moldovan ID; Ghinda D; Gotfrit R; Torres CH; Zakhari N; Chakraborty S; Woulfe J; Jansen G; McInnes MD; Thornhill RE; Cameron I; AlKherayf F
    J Magn Reson Imaging; 2021 Feb; 53(2):416-426. PubMed ID: 32940938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma.
    Sun C; Xiao L; Zhao Y; Shi J; Yuan Y; Gu Y; Zhang F; Gao X; Yang Y; Yang R; Qin J; Zhang J; Wang C; Wang Y; Wang Z; Hu P; Chang T; Wang L; Wang G; Chen H; Li Z; Ye J
    Transl Oncol; 2020 Apr; 13(4):100758. PubMed ID: 32208352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.